SVCM
PHAT icon

Saturn V Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Saturn V Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-874,590
Closed -$15.8M – 28
2024
Q3 		$15.8M Buy
874,590
+281,284
+47% +$3.93M 5.65% 8
2024
Q2 		$6.11M Buy
593,306
+92,319
+18% +$951K 2.31% 18
2024
Q1 		$5.32M Buy
500,987
+340,912
+213% +$2.9M 2.13% 16
2023
Q4 		$1.46M Buy
+160,075
New +$1.38M 0.56% 21

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Saturn V Capital Management's PHAT Position: Q4 2024 in Review

Saturn V Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q4 2024, closing a stake of 874,590 shares — an estimated $15.8M sold.

Saturn V Capital Management first reported a position in PHAT in Q4 2023 and held it in 4 quarters. The position peaked at $15.8M in Q3 2024. 144 funds tracked by Wall St. Rank hold PHAT as of Q4 2024.

  • Saturn V Capital Management reported no remaining Phathom Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 874,590 Phathom Pharmaceuticals shares in Q4 2024, an estimated $15.8M.
  • Saturn V Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Saturn V Capital Management's Phathom Pharmaceuticals position peaked at $15.8M in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2024.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.